PT. RICHMOND, Calif., Dec. 7 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President & Chief Executive Officer, will participate in an expert panel on "Drug Development in a Changed Environment" at the RBC Capital Markets 2007 Healthcare Conference at the Westin New York Hotel at Times Square on Thursday, December 13, 2007 at 10:00 AM Eastern Time.
The multi-company panel will be moderated by Ken Trbovich, Vice President, Capital Markets at RBC, and will be available at the following link via webcast: http://www.wsw.com/webcast/rbc84/panel24.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to
provide additional uses and enhanced clinical benefits for existing active
agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate
lozenge), is a low dose sublingual formulation of zolpidem that is
currently in late phase 3 clinical trials for the treatment of insomnia in
patients who awaken in the middle of the night and have difficulty
returning to sleep. Another product being developed by Transcept is
TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for
the treatment of dopamine associated psychiatric disorders. TO-2060 is
currently the subject of an initial proof of concept trial in the treatment
of alcohol use disorder. For more information, please visit the company's
website at: http://www.transcept.com.
Transcept Pharmaceuticals, Inc. The Ruth Group
Michael Gill Investors / Media
Director of Communications Stephanie Carrington / Jason Rando
(510) 215-3575 (646) 536-7017 / 7025
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved